Immunome (NASDAQ:IMNM) Earns “Outperform” Rating from Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued on Friday, Benzinga reports. They presently have a $33.00 target price on the stock. Wedbush’s target price indicates a potential upside of 172.50% from the stock’s current price.

Separately, Piper Sandler cut their target price on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $29.00.

Immunome Trading Up 0.8 %

NASDAQ IMNM opened at $12.11 on Friday. Immunome has a 12 month low of $6.93 and a 12 month high of $30.96. The stock has a 50-day simple moving average of $13.93 and a 200 day simple moving average of $14.26. The company has a market capitalization of $727.21 million, a PE ratio of -1.57 and a beta of 1.76.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The company had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.62 million. As a group, sell-side analysts predict that Immunome will post -1.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunome

In other news, CFO Max Rosett sold 14,380 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at $760,090.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Immunome news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the transaction, the insider now directly owns 16,000 shares of the company’s stock, valued at $222,880. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capstone Investment Advisors LLC acquired a new stake in shares of Immunome in the first quarter valued at about $1,044,000. Swiss National Bank acquired a new position in shares of Immunome during the 1st quarter worth approximately $1,762,000. Sei Investments Co. bought a new stake in shares of Immunome during the 1st quarter worth approximately $469,000. Lord Abbett & CO. LLC acquired a new stake in shares of Immunome in the 1st quarter valued at approximately $10,994,000. Finally, Vanguard Group Inc. grew its stake in shares of Immunome by 16.1% in the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after buying an additional 279,712 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.